Efficacy of checkpoint inhibition after CAR-T failure in aggressive B-cell lymphomas: outcomes from 15 US institutions

By sjmartinez • August 14, 2023

Major A, Yu J, Shukla N, Che Y, Karrison TG, Treitman R, Kamdar MK, Haverkos BM, Godfrey J, Babcook MA, Voorhees TJ, Carlson S, Gaut D, Oliai C, Romancik JT, Winter AM, Hill BT, Bansal R, Villasboas Bisneto JC, Nizamuddin IA, Karmali R, Fitzgerald LA, Stephens DM, Pophali PA, Trabolsi A, Schatz JH, Hu M, Bachanova V, Slade MJ, Singh N, Ahmed N, McGuirk JP, Bishop MR, Riedell PA, Kline J. Efficacy of checkpoint inhibition after CAR-T failure in aggressive B-cell lymphomas: outcomes from 15 US institutions. Blood Adv. 2023 Aug 22;7(16):4528-4538. doi: 10.1182/bloodadvances.2023010016. PMID: 37026796.

Tags: Fellow, Hematology/Oncology, Publications

Genomic and Transcriptomic Profiling of Radiation-Resistant, Locally Recurrent Prostate Cancer

Neilsen BK, Huang RR, Valle LF, Proudfoot JA, Davicioni E, Zhang L, Ryg U, Schulz-Jaavall M, Weidhaas JB, Santoso M, Parmisano S, Calais J, Reiter[...]

Immune Checkpoint Inhibitor Myocarditis Masquerading as Brugada Syndrome

Talishinsky A, Bachour K, Lin C, Zakka P, Bassam K, Bull L, Garon E, Krokhaleva Y, Hanna P, Yang EH. Immune Checkpoint Inhibitor Myocarditis Masquerading[...]

Domvanalimab and zimberelimab in advanced gastric, gastroesophageal junction or esophageal cancer: a phase 2 trial

Janjigian YY, Oh DY, Pelster M, Wainberg ZA, Prusty S, Nelson S, DuPage A, Thompson A, Koralek DO, Sison EAR, Rha SY. Domvanalimab and zimberelimab[...]